Nonacus was recently awarded an Innovate UK grant, to validate a novel, rapid method for sequencing respiratory viral genomes using nanopore sequencing. This method will provide more comprehensive information about the Sars-CoV-2 genome to support a post pandemic world and, with a respiratory viral panel in the pipeline, will provide surveillance of other respiratory diseases too. So, if your cough is not due to COVID-19, you will be able to find out which respiratory virus is causing it.

Nonacus scientists, together with researchers at the University of Cambridge, are working on the development of a novel, non-invasive test for coeliac disease that works even if the patient is already on a gluten-free diet.

Suspected coronavirus patients could be asked to spit into a tube and post the sample to a lab, under plans for a new test being developed by a British firm. Read the interview with Nonacus Ltd in the Sunday Telegraph on how a partnership with Chronomics has led to the development of a spit test for COVID-19.

The impact of the coronavirus is being felt right across the UK and I hope that you, your family and your friends remain safe and well.

With yesterday’s announcement from the government, we know that this impact will be wide ranging and may be having a knock on effect on your laboratory. We are hearing of laboratory closures during the self-isolation period and labs operating with a skeleton staff, all of which puts pressure on laboratory services.

Birmingham, UK, 16 October 2019: Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product to simplify the generation and interpretation of molecular and cytogenomic data. The new product has been co-developed with digital health technology company, Congenica Ltd, which specialises in software solutions that enable accelerated interpretation of complex genomic data to improve disease diagnosis.

We are excited to announce that Nonacus are recruiting! Following the successful launch of our Cell3TM DNA product range we are now growing the team and are seeking a highly motivated experienced Quality Assurance (QA) / Quality Control (QC) Production Scientist to join our team. The full job description and details on how to apply…

New direct from plasma cfDNA test provides results in three hours. Since 2011 the NHS has been using cell free DNA (cfDNA) in fetal sex testing to identify pregnancies at high risk of sex-linked disorders. This test is done by extracting cfDNA from maternal plasma: a process that is slowing down results for patients.

Nonacus reviews latest accreditation efforts. Currently, the RhD genotyping landscape doesn’t feature a full EQA (European Quality Assurance) scheme but this latest report published in Blood Transfusion represents a big step forward towards an EQA. The authors have set themselves an objective to implement a regular EQA scheme through their working group. Chris Sale- CEO